MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition-Reference-Cited by-同舟云学术

MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition

Published:2015-09-25 Issue:3 Volume:355 Page:397-409
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Fell Matthew J.,Mirescu Christian,Basu Kallol,Cheewatrakoolpong Boonlert,DeMong Duane E.,Ellis J. Michael,Hyde Lynn A.,Lin Yinghui,Markgraf Carrie G.,Mei Hong,Miller Michael,Poulet Frederique M.,Scott Jack D.,Smith Michelle D.,Yin Zhizhang,Zhou Xiaoping,Parker Eric M.,Kennedy Matthew E.,Morrow John A.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference32 articles.

1. Loss of Leucine-Rich Repeat Kinase 2 (LRRK2) in Rats Leads to Progressive Abnormal Phenotypes in Peripheral Organs

2. Localization of LRRK2 to membranous and vesicular structures in mammalian brain

3. LRRK2 Low-penetrance Mutations (Gly2019Ser) and Risk Alleles (Gly2385Arg)—Linking Familial and Sporadic Parkinson’s Disease

4. Brain Penetrant LRRK2 Inhibitor

5. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease

Cited by 247 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Parkinson’s Disease;International Encyclopedia of Public Health;2025

2. Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2;2024-09-09

3. Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2;2024-09-09

4. Targeting Specific Kinase Substrates Rescues Increased Colitis Severity Induced by the Crohn’s Disease-Linked LRRK2-N2081D Variant;2024-09-05

5. Discovery and Optimization of N-Heteroaryl Indazole LRRK2 Inhibitors;Journal of Medicinal Chemistry;2024-09-04